Principal Scientist, CDx IHC Development

SystImmune is a leading and well-funded clinical-stage biopharmaceutical company located in Bothell, WA and Princeton, NJ. It specializes in developing innovative cancer treatments using its established drug development platforms, focusing on bi-specific, multi-specific antibodies, and antibody-drug conjugates (ADCs). SystImmune has multiple assets in various stages of clinical trials for solid tumor and hematologic indications. Alongside ongoing clinical trials. SystImmune has a robust preclinical pipeline of potential cancer therapeutics in the discover and IND-enabling stages, representing cutting-edge biologics development. We offer an opportunity for you to learn and grow while making significant contributions to the company's success.We are seeking a Principal Scientist to provide technical leadership for the development of immunohistochemistry (IHC) companion diagnostics supporting oncology drug programs. This individual will serve as a subject matter expert responsible for CDx assay strategy, analytical validation, and clinical implementation from early feasibility through regulatory submission and commercialization readiness.The Principal Scientist will lead complex CDx IHC development initiatives, ensure compliance with global regulatory and quality standards, and influence biomarker strategy through deep technical expertise. This is a hands‑on scientific leadership role requiring strong collaboration with pathology, translational science, regulatory, clinical development, and external diagnostic partners to ensure successful CDx execution aligned with therapeutic timelines.This position is full-time onsite at our Bothell, WA location.ResponsibilitiesCDx IHC Kit Development & StrategyLead development of IHC-based CDx assays and kits from early feasibility through IVD readinessDefine assay design, platform selection, and development strategy aligned with CDx regulatory expectationsOversee antibody selection, assay optimization, and standardization across platforms (e.g., Ventana, Dako, Leica)Guide development of scoring algorithms, cut-offs, and interpretation frameworks with pathology leadershipAnalytical Validation & Design ControlLead analytical validation strategy and execution for CDx IHC assays, including sensitivity, specificity, precision, accuracy, and robustnessEnsure validation activities meet regulatory expectations and are conducted under design controlOversee preparation and approval of validation protocols, reports, and technical documentationEnsure traceability, risk management, and documentation in compliance with QSR 820 and ISO 13485Clinical & CDx ImplementationProvide oversight for implementation of CDx IHC assays in clinical trials and central laboratoriesEnsure assay consistency, pathologist alignment, and scoring harmonization across sitesSupport biomarker strategy, sample plans, and clinical cut-off justificationRegulatory & QualityPartner with Regulatory Affairs and QA to support CDx regulatory strategy and submissions (e.g., IND/IDE, PMA/IVD)Ensure compliance with global regulatory requirements (FDA, NMPA, IVDR)Support bridging strategies from RUO/LDT to IVD CDx and contribute to regulatory interactionsDrive alignment with QMS, including design controls, change control, and audit readinessCross-Functional LeadershipAct as subject matter expert for CDx IHC development across internal and external stakeholdersLead collaborations with CROs, central labs, and IVD partnersMentor team members and contribute to building CDx development capabilitiesQualificationsPhD in Pathology, Immunology, Molecular Biology, or related life science field8–12+ years of industry experience in CDx, IVD, or biomarker assay developmentProven experience leading IHC assay development and analytical validationStrong knowledge of design controls and QMS (21 CFR Part 820, ISO 13485)Experience supporting clinical trials and CDx regulatory submissionsStrong understanding of IHC scoring methods (TPS, CPS, H-score)Experience working in oncology biomarker development environmentsPreferred QualificationsExperience with approved or late-stage CDx programsBackground in oncology biomarkers (e.g., NSCLC, GI cancers)Experience interacting with health authorities (FDA, NMPA, EU)Compensation and Benefits:The expected base salary range for this position is $130,000 - $160,000 annually. Actual compensation will be based on a variety of factors, including but not limited to a candidate’s level qualifications, experience, and skills.While most offers typically fall within the low to mid-point of the range, we may extend an offer toward the higher end for exceptional candidates whose background and expertise exceeds the requirements of the role.SystImmune is a leading and well-funded biotech company with a bright future. We offer an opportunity for you to learn and grow while making significant contributions to the company’s success. SystImmune offers a comprehensive benefits package including: 100% paid employee premiums for medical/dental/vision, also STD, LTD, a 401(k) plan with a 50% company match of up to 3% and a vesting schedule of only 5 years, 15 PTO days per year, sick leave, plus 11 paid holidays and MORE.We offer an opportunity for you to learn and grow while making significant contributions to the company’s success.SystImmune is an Equal Opportunity Employer. We welcome diverse talent and encourage all qualified applicants to apply.